Aptar CSP Technologies Expands Service Offerings With Launch of cGMP Early Stage Clinical Manufacturing Site for Tablet & Capsule-Based Drug Products

Aptar CSP Technologies, part of AptarGroup, Inc. and a global leader in active material science solutions, announced the expansion of its service offerings with the launch of a cGMP-compliant manufacturing facility in New Jersey. The new site will support clinical packaging for oral solid dose (OSD) and capsule-based DPI drugs utilizing Aptar CSP’s proprietary Activ-Polymer platform and Activ-Blister™ solutions.

The expansion addresses growing market demand for enhanced drug stability and nitrosamine risk mitigation. Aptar CSP’s Activ-Blister technology integrates a highly-engineered active film material into thermoform and cold-form blister packaging configurations, creating a microclimate that protects individual doses from moisture, oxygen, VOCs, and degradation, including reducing the risk of N-nitrosamine formation. The technology delivers customizable, dose-specific protection tailored to the unique stability needs of each drug formulation.

“Launching this cGMP facility reinforces our commitment to delivering streamlined access to innovative active material science technologies for patients and pharmaceutical partners,” said Badre Hammond, Vice President Commercial Operations and General Manager, Aptar CSP Technologies. “By offering early-stage clinical services with custom-designed equipment, we simplify adoption, eliminate implementation barriers, and help avoid lengthy reformulation or repackaging efforts.”

The new site, which is the result of a collaboration with MOD3 Pharma, will offer services including R&D support, Phase I and II clinical material manufacturing, full CMC package (Chemistry, Manufacturing, and Controls), stability studies, and clinical supply management.

Aptar CSP’s 3-Phase Activ-Polymer platform technology is trusted worldwide to protect high-value products such as drugs, diagnostics, probiotics, medical devices, and implants.

Representatives from Aptar CSP Technologies and its technical partners will be available for meetings at RDD Europe 2025 in Estoril (Lisbon), Portugal, May 6-9. To schedule a meeting at RDD Europe, please contact Dr. Paul Shields, CEO at MOD3 Pharma at pshields@mod3pharma.com. For commercial inquiries, contact Francois Bidet, VP of EMEA Business Development, Aptar CSP Technologies at francois.bidet@aptar.com.

Aptar CSP Technologies is part of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar CSP Technologies leverages its active material science expertise to transform ideas into market opportunities, accelerate and de-risks the product development process, and provide complete solutions that improve consumers’ and patients’ lives. The company offers a complete set of services from concept ideation, to design and engineering, to product development, global production, quality control, and regulatory support that results in expedited speed-to-market. For more information, visit www.csptechnologies.com and www.aptar.com